Angiotensin II and calcium blockers prevent glomerular phenotypic changes in remnant kidney model

Journal of the American Society of Nephrology

Volumn 7, Issue 5, 1996, Pages 687-693

  Hamaguchi, Akinori ^a   Kim, Shokei ^a   Wanibuchi, Hideki ^a   Iwao, Hiroshi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II Type 1 receptor; Calcium antagonist; Desmin; Glomerulosclerosis; smooth muscle actin

Indexed keywords

ALPHA ACTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; DESMIN; MANIDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GLOMERULOPATHY; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; KIDNEY MASS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTIAL NEPHRECTOMY; PHENOTYPE; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 0030370127     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Johnson RJ, Iida H, Alpers CE, et al.: Expression of smooth muscle cell phenotype by rat mesanglal cells in immune complex nephritis. J Clin Invest 1991;87:847-858.
2. Johnson RJ, Floege J, Yosimura A, Iida H, Couser WG, Alpers CE: The activated mesangial cell: A glomerular "Myofibroblast"? J Am Soc Nephrol 1992;2:S190-S197.
3. Johnson RJ: The glomerular response to Injury: Progression or resolution? Kidney Int 1994;45:1769-1782.
4. Young BA, Johnson RJ, Alpers CE, et al.: Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995;47:935-944.
5. Floege J, Burns MW, Alpers CE, et al.: Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 1992; 41:297-309.
6. Alpers CE, Hudkins KL, Gown AM, Johnson RJ: Enhanced expression of "muscle-specific" actin in glomerulonephritis. Kidney Int 1992;41:1134-1142.
7. Tolins JP, Raij L: Antihypertensive therapy and progression of chronic renal disease. Are there renoprotective drugs? Semin Nephrol 1991;11:538-548.
8. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progression renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
9. Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992;90:766-771.
10. Anderson S: Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass. Hypertension (Dallas) 1991;17:288-295.
11. Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD: Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993;43:808-814.
12. Chanutin A, Ferris EB: Experimental renal insufficiency produced by partial nephrectomy. I. Control diet. Arch Int Med 1932;49:767-787.
13. Morrison AB: Experimental chronic renal insufficiency. Meth Achiev Exp Pathol 1966;1:455-475.
14. Raij L, Azar S, Keane W: Mesangial immune injury, hypertension, and progressive glomerular damege in Dahl rats. Kidney Int 1984;26:137-143.
15. Weibel ER. Stereological Methods: Practical Methods for Biological Morphometry. London; Academic Press Inc.; 1979:51-57.
16. Hamaguchi A, Kim S, Ohta K, et al.: Transforming growth factor-β1 expression and phenotypic modulation in the kidney of hypertensive rats. Hypertension (Dallas) 1995;26:119-207.
17. Kurki P, Vanderlaan M, Dolbeare F, Gray J, Tan EM: Expression of proliferating cell nuclear antigen (PCNA)/ cyclin during the cell cycle. Exp Cell Res 1986;166:209-219.
18. Couser WG, Johnson RJ: Mechanisms of progressive renal disease in glomerulonephritis. Am J Kidney Dis 1994;23:193-198.
19. Kim S, Ohta K, Hamaguchi A, et al.: Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Int 1994;46: 1346-1358.
20. Kim S, Ohta K, Hamaguchi A, et al.: Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension (Dallas) 1994;24:195-204.
21. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-1930.
22. Yamamoto T, Mundy CA, Wilson CB, Blanztz RC: Effect of mesangial cell lysis and proliferation on glomerular hemodynamics in the rat. Kidney Int 1991;40:705-713.
23. Harris RC, Haralson MA, Badr KF: Continuous stretch-relaxation in culture alter rat mesangial cell morphology, growth, characteristics, and metabolic activity. Lab Invest 1992;66:548-554.
24. Harris RC, Akai Y, Yosida T, Homma T: The role of physical forces in alterations of mesangial cell function. Kidney Int 1994;45(Suppl 45):S17-S21.
25. Yoshioka T, Shiraga H, Yoshida Y, et al.: "Intact nephrons" as the primary origin of proteinuria in chronic renal disease. Study in the rat model of subtotal nephrectomy. J Clin Invest 1988;82:1614-1623.
26. Tojo A, Kimura K, Matsuoka H, Sugimoto T: Effects of manidipine hydrochloride on the renal microcirculation in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992;20:895-899.
27. Wolf G, Neilson EG: Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993;3:1531-1540.
28. Ausiello DA, Kreisberg JI, Roy C, Karnovsky MJ: Contraction of cultured rat glomerular cells of apparent mesangial origin after stimulation with angiotensin II and arginine vasopressin. J Clin Invest 1980;65:754-760.
29. Johnson RJ, Alpers CE, Yosimura A, et al.: Renal injury from angiotensin II-mediated hypertension. Hypertension (Dallas) 1992;19:464-474.
30. Shultz PJ, Raij L: Inhibition of human mesangial cell proliferation by calcium channel blockers. Hypertension (Dallas) 1990;15(Suppl 1):I76-I80.
31. Fujiwara Y, Kikkawa R, Kitamura E, Takama T, Shigeta Y: Angiotensin II effects upon glomerular intracapillary volume in the rat. Renal Physiol 1984;7:344-348.